Drug Shortage Report for CIPROFLOXACIN INTRAVENOUS INFUSION BP
Report ID | 236750 |
Drug Identification Number | 02304759 |
Brand name | CIPROFLOXACIN INTRAVENOUS INFUSION BP |
Common or Proper name | CIPROFLOXACIN 400MG 200ML |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | CIPROFLOXACIN |
Strength(s) | 2MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
Additional packaging sizes | 10LIIF |
ATC code | J01MA |
ATC description | QUINOLONE ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2024-10-28 |
Actual start date | |
Estimated end date | 2024-12-31 |
Actual end date | 2024-09-30 |
Shortage status | Avoided shortage |
Updated date | 2024-09-30 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2024-09-30 | French | Compare |
v3 | 2024-09-30 | English | Compare |
v2 | 2024-09-05 | French | Compare |
v1 | 2024-09-05 | English | Compare |
Showing 1 to 4 of 4